CellCentric’s oral drug candidate CCS1477 addresses the large and growing population of
AACR poster 2018: http://www.cellcentric.com/aacr-poster-2018.
CellCentric has developed CCS1477, a potent, selective
There is literature evidence that inhibiting p300/CBP may also have relevance to other tumour types.
Professor Tim Somervaille,
As well as collaborating with The CRUK Manchester Institute, CellCentric has ongoing translational research looking beyond prostate cancer, with The Northern Institute for Cancer Research, Newcastle (Dr Luke Gaughan), The University of Leeds (Prof Maggie Knowles), The University of Cambridge (Prof Brian Huntly) and Columbia University, New York (Prof Laura Pasqualucci).
Dr Nigel Brooks, CellCentric’s Director of Translational Science, added “CCS1477’s progress has relied on CellCentric’s excellent links to
CCS1477 has relevance to multiple cancer types, but notably late stage,
CellCentric is a privately held business, with Morningside Venture Investments as its lead investor. CCS1477’s progress has also benefited from awards from Innovate UK (BioMedical Catalyst) and the Prostate Cancer Foundation. The company maintains active collaborations with multiple research centres in Europe and the US.
For more information on the company, please go to www.cellcentric.com, and follow us on LinkedIn or twitter @CellCentric.